149505ae-e005-4aee-b144-5d697b52677e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 50
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.160
- PANCREAS_BETA_CELLS+0.120
- ALLOGRAFT_REJECTION+0.080
- HEME_METABOLISM+0.080
- BILE_ACID_METABOLISM+0.070
- P53_PATHWAY+0.070
- SPERMATOGENESIS+0.060
- KRAS_SIGNALING_DN+0.040
- TGF_BETA_SIGNALING+0.040
- APICAL_SURFACE+0.030
Top 10 suppressed
- E2F_TARGETS-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- G2M_CHECKPOINT-0.540
- MTORC1_SIGNALING-0.510
- MYC_TARGETS_V1-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.500
- MYC_TARGETS_V2-0.490
- CHOLESTEROL_HOMEOSTASIS-0.370
- UV_RESPONSE_UP-0.370
- MYOGENESIS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5c61f3fb-d3c5-4628-89a8-94bd513e8fa4 | — | — | 0.879 |
| 2 | C3N-03212 | — | cohortA1 | 0.864 |
| 3 | SRR2016932 | — | — | 0.858 |
| 4 | SRR1516074 | — | — | 0.856 |
| 5 | TCGA-E7-A6MF-01A-12R-A32O-07 | — | — | 0.848 |
| 6 | MBCProject_5856_T0B_RNA | — | A | 0.848 |
| 7 | SRR1516050 | — | — | 0.840 |
| 8 | C3N-01799 | — | cohortA1 | 0.836 |
| 9 | SRR1313099 | — | A | 0.834 |
| 10 | SRR11296800 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |